Valuation: Precigen, Inc.

Market Cap 2.82B 2.45B 2.32B 2.11B 3.94B 270B 3.96B 27.67B 10.7B 137B 10.59B 10.35B 439B P/E 2026 *
35.7x
P/E 2027 * 11.5x
Enterprise Value 2.82B 2.45B 2.32B 2.11B 3.94B 270B 3.96B 27.67B 10.7B 137B 10.59B 10.35B 439B EV / Sales 2026 *
12.1x
EV / Sales 2027 * 6.2x
Free-Float
87.38%
Yield 2026 *
-
Yield 2027 * -
1 day-1.52%
1 week+13.80%
Current month+12.48%
1 month+15.48%
3 months+61.72%
6 months+138.38%
Current year+86.48%
1 week 6.76
Extreme 6.76
8.04
1 month 6.54
Extreme 6.54
8.04
Current year 3.04
Extreme 3.04
8.04
1 year 2.99
Extreme 2.99
8.04
3 years 0.65
Extreme 0.6513
8.04
5 years 0.65
Extreme 0.6513
8.04
10 years 0.65
Extreme 0.6513
32.9
Manager TitleAgeSince
Chief Executive Officer 64 01/01/2020
Director of Finance/CFO 64 01/10/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 72 01/02/2008
Director/Board Member 78 01/02/2008
Director/Board Member 70 28/11/2011
Date Insider Type Main position Quantity % Market Cap. Importance
8/26/26 A Sell

Director

-185,000 0.0620%
8/25/26 A Exercice

Executive/Senior Manager

237,498 0.0796%
8/25/26 A Exercice

Chief Operating Officer

46,026 0.0154%
Change 5-day change 1-year change 3-year change Capi.($)
-1.52%+13.80%+105.13%+441.32% 2.82B
-0.23%+2.81%+50.34%+100.78% 1,027B
-0.93%+0.74%+53.62%+64.67% 651B
+0.13%+2.33%+18.53%+70.92% 467B
-0.48%+4.24%+37.21%+39.10% 350B
-0.21%+3.27%+19.65%+25.73% 268B
+0.72%+6.70%+11.06%+16.44% 257B
+0.66%+1.15%+38.38%+45.04% 205B
+0.63%+1.14%-28.76%-57.01% 190B
+0.04%+4.62%+32.34%+98.84% 187B
Average -0.19%+4.02%+33.75%+84.58% 360.49B
Weighted average by Cap. -0.23%+2.64%+34.72%+61.50%

Financials

2026 *2027 *
Net sales 233M 203M 192M 174M 326M 22.31B 328M 2.29B 884M 11.34B 875M 856M 36.3B 454M 396M 375M 340M 636M 43.52B 639M 4.46B 1.73B 22.12B 1.71B 1.67B 70.8B
Net income 83.08M 72.37M 68.49M 62.23M 116M 7.96B 117M 816M 315M 4.04B 312M 305M 12.95B 257M 224M 212M 193M 360M 24.62B 362M 2.52B 976M 12.51B 966M 944M 40.06B
Net Debt - -
Logo Precigen, Inc.
Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Employees
160
Date Price Change Volume
18/09/26 $7.790 -1.02% 754,388
17/09/26 $7.870 +5.85% 9,364,227
16/09/26 $7.435 +6.21% 8,226,554
15/09/26 $7.000 +2.19% 2,779,394
14/09/26 $6.850 0.00% 2,825,661
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
7.870USD
Average target price
14.50USD
Spread / Average Target
+84.24%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PGEN Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!